TMC Still Optimistic About Cangrelor Approval Despite Negative Opinion
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Company seemed positive about the prospects for approval of its anti-clotting drug, even though an advisory committee voted against approval just a week ago.
You may also be interested in...
Cangrelor Can’t Escape Its Past At FDA Advisory Committee
The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.
Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No
As The Medicines Co.’s anticlotting drug heads to the Cardiovascular and Renal Drugs Advisory Committee, questions about comparator dosing and timing and the severity of bleeding events will be on the agenda.
Can The Medicines Company Rebound From A Phase III Blow?
Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.